Novavax | NVAX - Assets


Novavax reported $1.04B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Adma Biologics USD 665.18M 40.94M Mar/2026
Agenus USD 186.46M 40.34M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Cassava Sciences USD 108.37M 9.99M Mar/2026
Geron USD 534.12M 36.42M Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
MannKind USD 744.4M 47.78M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 11.49B 850M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 1.04B 133.35M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
TG Therapeutics USD 1.53B 465.58M Mar/2026